Application for CARB-X Funding Round 4 is now open: 

• Direct-acting small molecule antibiotics: Funding Round 4 will be open for Expressions of Interest November 12 through November 19, 2019, 5 PM ET. The scope of Round 4 is restricted to new classes of antibiotics and/or new targets for therapeutics.

You can find all the information you need at https://carb-x.org/apply/. Please review the information in the sections under the Apply tab.

Please read the scope of each round carefully at https://carb-x.org/apply/what-carb-x-funds/, and note the timing that is relevant to your project.

UPDATE: SUBMISSIONS CLOSED ON MAY 28TH.  Per an announcement on FedBizOpps, abstract acceptance is temporarily on hold due to a lack of available funding. 

Apply now! DRIVe's new EZ-BAA application is streamlined, fast and user-friendly.

The North Carolina Biotechnology Center is pleased to announce the Biomedical Advanced Research and Development Authority (BARDA) Division of Research, Innovation and Ventures (DRIVe) simplified application process, called the EZ BAA, is now open for business. Medical product developers, research teams, and companies offering disruptive solutions to health security threats are invited to submit abstracts beginning today using this simplified EZ BAA process.

BARDA is looking for the most innovative products and technologies to protect Americans from the most serious systemic, natural and intentional health security threats. Our goal is to build a portfolio of products representing disruptive innovative approaches that will transform health security.

Applications accepted through this streamlined process must offer transformative innovation, products and technologies to protect Americans from health security threats. This application process is a business-friendly simple abstract.
 
In-scope priority areas include: products and solutions to reduce illness and death from sepsis as part of DRIVe’s Solving Sepsis initiative; technologies and processes to identify infections and exposures to biological and other health threats, as outlined in the Early Notification to Act, Control, and Treat (ENACT) initiative; and tools and techniques to mitigate the damages and loss of life associated with catastrophic events.

Applying is simple:

• Download the application form from the website.
• Submit a technical abstract no longer than 2,000 words.
• Include a cost proposal of an additional 2,000 words or less.
• Proposed costs should not exceed $749,000.

What happens next:

• Once submitted, DRIVe’s experts will review the application to ensure it is within scope and meets DRIVe criteria.
• As the applicant, you’ll be notified of the review results within 30 days of your submission.

Learn more about the DRIVe EZ-BAA review criteria.

For more information, visit the DRIVe website.

Have questions? Looking for more information? Contact DRIVeContracting@hhs.gov

NC-based resource:
Emil Runge, Program Manager
erunge@ffvcnc.org
Mobile: (404) 668-2136
First Flight Health Security Accelerator
2 Davis Drive, Research Triangle Park, NC

The Medical Technology Enterprise Consortium (MTEC) is excited to post this announcement for a Request for Project Information (RPI) focused on Traumatic Brain Injury Drug Treatment (TBI DT) - to rapidly conduct Phase 2 clinical trials on traumatic brain injury (TBI) drug candidates and identify at least one TBI drug candidate for advancement into a Phase 3 clinical trial. The end goal of the TBI DT program is a commercially-available TBI drug that is approved by the U.S. Food and Drug Administration (FDA) to treat moderate to severe TBI (i.e., patients presenting with a Glasgow Coma Scale (GCS) score of =12, or 13-15 with evidence of intracranial injury on imaging (CT or MRI) referable to trauma).

Additional information on this RPI, including background material and guidance for the preparation of Project Information Papers to MTEC, can be found here:  https://www.fbo.gov/spg/USA/USAMRAA/DAMD17/MTEC-19-11-TBI-DT/listing.html

For inquiries regarding this announcement, please direct your correspondence to the following contacts:

Technical questions and Membership questions
Dr. Lauren Palestrini, MTEC Director of Research, Lauren.Palestrini@officer.mtec-sc.org

Administrative questions
Ms. Kathy Zolman, MTEC Interim Executive Director, Kathy.zolman@ati.org

The United States Army Medical and Materiel Command's (USAMRMC) mission is to provide solutions to medical problems of importance to the American Service member at home and abroad, as well as to the general public at large. Extramural research and development programs play a vital role in the fulfillment of the objectives established by the USAMRMC.

The FY18-FY22 USAMRMC Broad Agency Announcement (BAA) is intended to solicit extramural research and development ideas. Research and development funded through the BAA are intended and expected to benefit and inform both military and civilian medical practice and knowledge.
Read more information.